Gufic Biosciences Ltd Stock Price Today (NSE: GUFICBIO)
Fundamental Score
Gufic Biosciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Gufic Biosciences Ltd share price today is ₹389.85, up +1.54% on NSE/BSE as of 31 July 2026. Gufic Biosciences Ltd (GUFICBIO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.98K (Cr). The 52-week high for GUFICBIO share price is ₹448.00 and the 52-week low is ₹268.00. At a P/E ratio of 63.08x, GUFICBIO is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 9.98% and a debt-to-equity ratio of 0.61.
Gufic Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance
Gufic Biosciences Ltd share price chart: -1.14% return over the past month. 52-week high ₹448.00, 52-week low ₹268.00.
Gufic Biosciences Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹383.00 | ₹391.95 | ₹383.00 | ₹389.85 | 37.68K (Cr) | |
| ₹383.00 | ₹389.00 | ₹377.70 | ₹383.95 | 32.34K (Cr) | |
| ₹387.95 | ₹388.80 | ₹380.30 | ₹382.35 | 35.37K (Cr) | |
| ₹380.35 | ₹394.40 | ₹373.25 | ₹387.75 | 67.78K (Cr) | |
| ₹384.00 | ₹386.50 | ₹377.60 | ₹382.25 | 48.31K (Cr) | |
| ₹379.25 | ₹384.00 | ₹362.50 | ₹378.85 | 47.08K (Cr) | |
| ₹382.00 | ₹385.90 | ₹375.50 | ₹377.15 | 47.84K (Cr) | |
| ₹392.00 | ₹399.00 | ₹386.10 | ₹396.70 | 88.65K (Cr) | |
| ₹378.50 | ₹395.00 | ₹378.45 | ₹393.75 | 80.14K (Cr) | |
| ₹388.30 | ₹389.45 | ₹378.30 | ₹381.90 | 69.33K (Cr) |
Gufic Biosciences Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹407.50 | ₹409.90 | ₹362.50 | ₹389.85 | -4.33% | |
| ₹342.00 | ₹448.00 | ₹336.00 | ₹407.05 | +19.02% | |
| ₹285.00 | ₹341.95 | ₹273.15 | ₹333.85 | +17.14% | |
| ₹275.15 | ₹312.40 | ₹275.15 | ₹284.60 | +3.43% | |
| ₹275.00 | ₹303.25 | ₹268.00 | ₹273.80 | -0.44% | |
| ₹299.30 | ₹319.80 | ₹274.45 | ₹283.05 | -5.43% | |
| ₹337.00 | ₹342.90 | ₹293.05 | ₹307.25 | -8.83% | |
| ₹356.00 | ₹360.00 | ₹316.00 | ₹336.00 | -5.62% | |
| ₹325.40 | ₹373.40 | ₹310.50 | ₹355.65 | +9.30% | |
| ₹355.10 | ₹370.00 | ₹315.50 | ₹325.40 | -8.36% | |
| ₹363.00 | ₹374.60 | ₹346.80 | ₹354.45 | -2.36% | |
| ₹382.00 | ₹387.00 | ₹352.45 | ₹366.95 | -3.94% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Gufic is a small-cap pharma company hoping for an international and API-led turnaround, but faces immediate headwinds and governance concerns.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Gufic Biosciences reported Q3 FY26 results with a mixed performance. Revenue stood at , a QoQ decrease of 2.38% but an 11.37% YoY increase. Net profit was , down 26.16% QoQ and 35.68% YoY. The company also received a penalty demand of s from the Income Tax Department for under-reported income in FY24.
CORE STORY (THE REAL GAME)
Gufic is trying to transition from a pure domestic formulations player to a more integrated API and international player. The market is watching if they can execute this shift while maintaining margins.
- Q3 results show a decline in net profit
- Company received a penalty for under-reporting income
- High P/E suggests overvaluation
- Successful API integration
- Faster international expansion
- Improved domestic sales
- Small-cap: liquidity risk
- High P/E: valuation stretch
- Negative free cash flow
DII increased holdings slightly (Δ 0.28%), while promoter holdings decreased marginally (Δ -0.01%).
Indian pharma sector is projected to reach $130 billion by 2030, driven by global demand and innovation.
No - Free Cash Flow 5Y: ₹-184.0 Cr
Gufic needs to demonstrate successful execution of its international and API strategies to justify its valuation. Focus on profitability and cash flow generation is crucial.
Primary Thesis Risk
Failure to execute international expansion and API integration will lead to a significant de-rating.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Gufic Biosciences Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gufic Biosciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GUFICBIO across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (17.81%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (158.09%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (22.94%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (14.04% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Balanced Promoter Holding (72.50%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (9.98%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 63.08x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (2.08% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-246.01 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 4.25%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Gufic Biosciences Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Gufic Biosciences Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Gufic Biosciences LtdGufic Bioscienc...Selected✓ GUFICBIO • 509079 | 46.2/100 | ₹389.85₹390 | ₹3983.69₹3983.69 | 63.08Average 63.1 Average | 9.98%Poor 9.98% Poor | 12.17%Average 12.17% Average | 0.61Good 0.6 Good | 7.39%Good 7.39% Good | 14.04%Good 14.04% Good | 0.03% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Gufic Biosciences Ltd PE Ratio History
Historical price-to-earnings ratio for GUFICBIO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹6.95 | ₹336.00 | 48.3x |
| FY 2024 | ₹8.74 | ₹455.30 | 52.1x |
| FY 2023 | ₹8.22 | ₹316.45 | 38.5x |
| FY 2022 | ₹9.89 | ₹226.45 | 22.9x |
| FY 2021 | ₹4.56 | ₹237.60 | 52.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Gufic Biosciences Ltd Dividend History
Annual cash dividends paid by GUFICBIO — dividend yield 0.03%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.00 Cr |
| FY 2024 | ₹0.97 Cr |
| FY 2023 | ₹1.04 Cr |
| FY 2022 | ₹0.92 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Gufic Biosciences Ltd Quarterly Performance
Latest quarterly metrics for GUFICBIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
22.94%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
158.09%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
14.04%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
7.39%
Compounded annual net profit growth over 5 years
Gufic Biosciences Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GUFICBIO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Gufic Biosciences Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Gufic Biosciences Ltd (GUFICBIO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Gufic Biosciences Ltd
About GUFICBIO (Gufic Biosciences Ltd)
Gufic Biosciences Ltd is a dynamic pharmaceutical entity carving a niche in the global healthcare landscape. The company distinguishes itself through a comprehensive approach, enco...mpassing research, development, manufacturing, and marketing of a diverse range of pharmaceutical products. Their focus extends beyond conventional medications, venturing into innovative therapeutic areas like critical care, fertility, and anti-infectives. Gufic Biosciences invests substantially in cutting-edge technology and adheres to stringent quality control measures, ensuring product efficacy and safety. With a growing portfolio of formulations and a dedication to patient well-being, the company is committed to expanding its reach and impact on healthcare systems worldwide. Gufic Biosciences operates a state-of-the-art manufacturing infrastructure that allows for the production of both active pharmaceutical ingredients (APIs) and finished dosage forms. Their expertise lies in the creation of complex molecules and specialized formulations, including lyophilized injectables which need specific controlled environment. The company takes pride in its robust supply chain management and adherence to international regulatory standards, enabling them to efficiently cater to the demands of diverse markets. By integrating sustainable practices into their operations, Gufic Biosciences strives to minimize its environmental footprint and contribute to a more responsible pharmaceutical industry. The company's strategic vision involves strengthening its presence in emerging markets and fostering collaborative partnerships to drive innovation and accelerate growth. They are actively pursuing opportunities to expand their product pipeline through strategic acquisitions and in-licensing agreements. Gufic Biosciences is also committed to building a skilled workforce and fostering a culture of continuous learning and development, enabling them to stay at the forefront of the ever-evolving pharmaceutical sector. Through its dedication to quality, innovation, and accessibility, Gufic Biosciences aspires to make a significant contribution to improving global health outcomes.
Company Details
Key Leadership
Corporate Events
GUFICBIO Share Price: Frequently Asked Questions
What is the current share price of Gufic Biosciences Ltd?
Gufic Biosciences Ltd (GUFICBIO) trades at ₹389.85 on NSE and BSE. Market cap ₹3.98K (Cr). Educational data only.
What is the P/E ratio of Gufic Biosciences Ltd?
Gufic Biosciences Ltd has a P/E of 63.08x vs industry average 34.89x.
What is the Bull Run score for Gufic Biosciences Ltd?
Gufic Biosciences Ltd has a Bull Run score of 46.2/100 based on 25+ financial parameters.
Does Gufic Biosciences Ltd pay dividends?
Gufic Biosciences Ltd has a dividend yield of 0.03%. Past dividends don't guarantee future payments.
What is the ROE of Gufic Biosciences Ltd?
Gufic Biosciences Ltd has ROE of 9.98%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Gufic Biosciences Ltd?
Gufic Biosciences Ltd has debt-to-equity of 0.61.
Is Gufic Biosciences Ltd a good investment?
Bull Run gives Gufic Biosciences Ltd a score of 46.2/100. This is not investment advice — consult a SEBI-registered advisor.